Ipswich Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-264
Closed -$204K 195
2026
Q1
$204K Buy
+264
New +$202K 0.05% 183
2024
Q4
Sell
-252
Closed -$265K 197
2024
Q3
$265K Hold
252
0.06% 167
2024
Q2
$265K Buy
252
+7
+3% +$6.79K 0.06% 167
2024
Q1
$236K Hold
245
0.06% 177
2023
Q4
$215K Hold
245
0.05% 181
2023
Q3
$202K Buy
+245
New +$193K 0.06% 180
2023
Q2
Sell
-245
Closed -$201K 195
2023
Q1
$201K Buy
+245
New +$185K 0.06% 182
2019
Q1
Sell
-50
Closed -$19K 334
2018
Q4
$19K Buy
+50
New +$18.3K 0.01% 335
2016
Q2
Sell
-150
Closed -$56K 283
2016
Q1
$56K Sell
150
-400
-73% -$165K 0.03% 220
2015
Q4
$299K Hold
550
0.13% 106
2015
Q3
$256K Sell
550
-50
-8% -$26.9K 0.12% 118
2015
Q2
$306K Sell
600
-50
-8% -$24.4K 0.14% 102
2015
Q1
$293K Sell
650
-50
-7% -$21.2K 0.13% 106
2014
Q4
$287K Hold
700
0.12% 103
2014
Q3
$252K Buy
+700
New +$235K 0.11% 110
2014
Q2
Sell
-700
Closed -$210K 146
2014
Q1
$210K Buy
+700
New +$216K 0.09% 121
2013
Q4
Sell
-700
Closed -$219K 148
2013
Q3
$219K Buy
+700
New +$184K 0.1% 129

Other funds holding REGN

Ipswich Investment Management's REGN Position: Q2 2026 in Review

Ipswich Investment Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 264 shares — an estimated $204K sold.

Ipswich Investment Management first reported a position in REGN in Q3 2013 and held it in 17 quarters. The position peaked at $306K in Q2 2015. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Ipswich Investment Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Ipswich Investment Management sold 264 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $204K.
  • Ipswich Investment Management first reported a position in Regeneron Pharmaceuticals in Q3 2013 and held it in 17 quarters.
  • Ipswich Investment Management's Regeneron Pharmaceuticals position peaked at $306K in Q2 2015.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Ipswich Investment Management's 13F filing for Q2 2026, filed 16 Jul 2026.